Our OncomineWorld events in 2020 and 2021 brought thousands of professionals together from around the world to advance understanding of next-generation sequencing in precision oncology research. The most recent meeting was held on April 29, 2021. We are pleased to announce that all event content is now available to access on demand!
The 2021 featured content includes presentations and discussions about hot and emerging biomarker testing, such as genomic instability, and new user experiences with the Ion Torrent Genexus NGS System in solid and hematologic tumor clinical research.
What can you expect from OncomineWorld 2021?
In addition to earning continuing education (CE) credits from on-demand presentations, you will also have access to all that the OncomineWorld universe has to offer -
For Research Use Only. Not for use in diagnostic procedures.
I joined Tata Medical centre, Kolkata in 2013 and work in the service diagnostic laboratory as a consultant pathologist, taking care of the rotuine haematopathology, lymphoma pathology, flow cytometry and Molecular genetics. I along with my team have been involved in developing and implementing flowcytometry based minimal residual disease assays for haematological diseases like ALL and multiple myeloma. I have stong interest in lymphoma pathology and report the lymph nodes/bone marrow aspirates/biopsies.
Under the guidance and vision of Dr Mammen Chandy (Director TMC) I have had the opportunity of successfully setting up affordable diagnostic molecular solutions for haematological and solid tumours using the latest techniques like NGS, digital PCR. Over the last 4-5 years we have successfully established and implemented molecular driven (Ion torrent based tissue genotyping for EGFR; digital PCR based T790M assays, cfDNA based EGFR genotyping, Oncomine comprehensve myeloid assays), standard treatment of care for our patients.
I am involved in running and teaching fellows from the fellowship courses in haematopathology and molecular pathology.
Dr. Ballester completed a B.S. in Biological Sciences at the University of Puerto Rico-Mayaguez, an M.D. degree at the UPR School of Medicine and a Ph.D. in pharmacology and genetics in the Department of Pharmacology at Vanderbilt University. Dr. Ballester joined the National Cancer Institute for Residency training in Anatomic Pathology (where he also served as chief resident). This was followed by fellowships in Molecular Genetic Pathology at Baylor College of Medicine and Neuropathology at the Houston Methodist/MDAnderson program. He is board certified by the American Board of Pathology in Anatomic Pathology, Neuropathology, and Molecular Genetic Pathology. Currently (since July 2017), Dr. Ballester has been an Assistant Professor in the Department of Pathology and Laboratory Medicine and the Department of Neurosurgery at the University of Texas Health Science Center in Houston. In addition to practicing clinical neuropathology, he serves as co-director of the Molecular Diagnostics Laboratory. He is also the principal investigator of an NIH-funded research program focusing on brain tumor biomarkers and minimally invasive diagnostic assays.
Cris graduated in Medicine and Surgery from the University of Auckland in 1989 and began research while working as a house surgeon in Dunedin, NZ. A PhD in the University of Auckland led to a four-year postdoctoral fellowship in the Walter and Eliza Hall Institute in Melbourne, Australia before six years in Cambridge University, UK, where he was a Fellow of St Edmunds College and developed a deep interest in genomics and bioinformatics. While there he co-founded a bioinformatics company that became listed on the Tokyo stock exchange in 2007. In 2005 he returned to the University of Auckland where he leads a cross-disciplinary research team of clinicians, cell biologists and data scientists who use genomics, systems biology and bioinformatics to better understand human disease, especially cancer. He leads the Genomics Into Medicine Strategic Research Initiative in Auckland and Chairs the Auckland Regional Tissue Bank Scientific Advisory Board. He is a Deputy Chair of the NZ Institute of Environmental Science and Research (ESR) and a Principle Investigator in the Maurice Wilkins Centre. Previously, he served as President of the NZ Society for Oncology and was Director of the Bioinformatics Institute at the University of Auckland.
Garret Hampton, PhD., is currently President, Clinical Sequencing and Oncology at ThermoFisher Scientific, responsible for leading the company’s clinical next generation sequencing strategy. Prior to joining Thermo Fisher Scientific, Garret was Senior Vice President, Clinical Genomics, at Illumina, responsible for the development of sequencing-based solutions in oncology, reproductive health and whole genome sequencing for the diagnosis of rare disease. Before joining Illumina, Garret held a variety of leadership positions at Genentech / Roche, Celgene, and The Genomics Institute of the Novartis Research Foundation, focused on drug target discovery, drug development and precision medicine. Prior to moving into industry, Garret was Assistant Professor of Medicine at UCSD, San Diego after a 2-year postdoctoral fellowship at the Salk Institute for Biological Studies. He received his PhD from the Imperial Cancer Research Fund (now Cancer Research UK) under Sir Walter Bodmer. He has authored over 150 peer reviewed articles and reviews, with 10,000 lifetime citations.
Andreas Jung is a Professor for experimental pathology specialising in tumor biology (immunebiology – T-cell activation), mathematics and molecular pathology. He is heading the unit Molecular Pathology of the Institute for Pathology of the University of Munich (LMU, Ludwig-Maximilians University)and research group on tumormorphogenesis concentrating on role and regulation of epithelio-mesenchymal transition (EMT) in colorectal cancer, testing of activity of mutations and resistance mutations in Ba/F3 modell, inhibitory role of approved and studies targeted ALK-inhibitors on EML4-ALK fusions (different variants) and effect of alpelisib on seldom PIK3CA-mutations He is a member of CCCM (comprehensive cancer cancer Munich), BZKF (Bavarian Centre for Cancer Research), DKG (German Cancer Society), AEK (working group experimental cancer research in the DKG), DKFZ (German Cancer Research centre), DKTK (German Cancer consortium), NGM (national network genomic medicine lung cancer).
Artur Kowalik, PhD, is a specialist in medical laboratory genetics. He is Head of the Department of Molecular Diagnostics at the Holycross Cancer Centre in Kielce. He also works at the Department of Medical Biology, Institute of Biology, Jan Kochanowski University in Kielce. The Department of Molecular Diagnostics performs molecular diagnostic tests for the patients treated in the Holycross Cancer Center in Kielce and many other centers in Poland. The group of tests performed includes stratification of patients with solid tumors for treatment with targeted therapies, detection of hereditary predisposition to cancer and diagnostics and monitoring of treatment effectiveness in hemato-oncology. The Department was the first in Poland to perform BRCA1/2 gene analysis for genetic counseling, using the NGS method. His research interests include cancer biology using modern molecular biology methods such as NGS and the application of liquid biopsy for cancer classification and monitoring of cancer treatment effectiveness.
Dr. Xia Li is the Scientific Medical Director of Genetics/Genomics Division at Sonora Quest Laboratories and Associate Professor of Pathology Department at University of Arizona. She oversees the operation of the laboratory and participates in the teaching and training of medical students and residents. Dr. Li has been working in the field of Genetics/Genomics diagnostics since 2008, and was certified in both Molecular and Cytogenetics through ABMGG. Before joining Sonora Quest Laboratories in 2016, Dr. Li was the Associate Director of Cytogenetics Laboratory at Cincinnati Children's Hospital from 2013 to 2016, and Associate Director of Cytogenetics Laboratory at AmeriPath Northeast from 2010 to 2013. She has extensive experience in cancer diagnostics using karyotyping, FISH, PCR, microarray and NGS technologies. She has published over 50 peer-reviewed articles and owns 2 patents. In her spare time, Dr. Li enjoys dancing, cooking, sewing, and hiking.
Dr Tony Lim graduated with MBBS from National University of Singapore in 1998. He later then joined the Department of Pathology in Singapore General Hospital and finished his training in 2006, obtaining both FRCPath and FRCPA fellowships. After his HMDP in Liver and Gastrointestinal pathology at Mt Sinai Hospital in New York in 2008, he has returned to practice General Surgical pathology with special interest in Liver and Gastrointestinal Pathology, biliary tract diseases like pancreatobilary cancers and lung cancer. In the years of clinical research setting, he has been involved in numerous clinical trials with pharmaceutical companies and has authored and co-authored numerous publications. Currently, he is the Clinical Director of Personalized OMIC Lattice for Advanced Research and Improving Stratification (POLARIS)@Sing Health, a Sing Health Research Core Platform which utilizes Next Generation Sequencing (NGS) technology to conduct tests and aims to translate novel scientific discoveries into clinically validated assays.
Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Director of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department. Since 1993 Dr Normanno's area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the identification of markers of response or resistance to anti-EGFR agents; the implementation of precision medicine in the path of care of cancer patients. Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and from 2020 President of the Italian Cancer Society (SIC). Dr Normanno is a reviewer for several peer-reviewed journals including Annals of Oncology, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Editor of Exploration of Targeted Anti-tumor Therapy and Associate Editor of BMC Cancer and Gene. Dr Normanno is the author of over 200 papers published in peer-reviewed journals with an H Index of 68.
Dr. Brandon Sheffield is an anatomic and molecular pathologist with the William Osler Health System. He is currently serving as the Medical Director of Immunohistochemistry and Molecular Pathology, and the Physician Lead of research for William Osler Health System. His professional focus is on the delivery of biomarkers to support precision oncology care in a community practice setting.
Dr. Lihui Wang obtained her quantification in Medicine in Peking University, China and her PhD degree in the University of Liverpool. She has been active in research on a variety of haematological malignancies in China, France, Scotland and England. Dr. Wang has been a Senior Clinical Scientist in Department of Haematology, Royal Liverpool University Hospital since year 2000. She has integrated both research project and NHS service to improve the molecular diagnosis, prognosis and monitoring for patients with haematological malignancies. Her research was mainly in investigating the role of BCR-ABL1 gene transcript monitoring in CML (Chronic Myeloid Leukaemia) patients under various clinical settings, the mechanism of tyrosine kinase inhibitor resistance in CML and the molecular mechanism of CML blast crisis (BC) transformation.
Dr. Wang has been involved in establishing and standardising BCR-ABL1 gene transcript monitoring in Liverpool, UK and across the world (WHO standard). Her role in NHS service was to establish and supervise molecular diagnostic and molecular monitoring service for patients with chronic myeloid leukaemia (CML), acute leukaemia and myeloproliferative neoplasms (MPN). Since 2018, Dr. Wang has been the Lead Scientist for Molecular Diagnostics, Haemato-oncology Diagnostic Service (HODS) in Royal Liverpool University Hospital. Her role was to establish and supervise the Haemato-oncology molecular diagnostic service for the region of Merseyside and Cheshire. Since 2019, Dr. Wang has been the Lead Scientist for NHS England Northwest Liverpool LCL Genomic Laboratory Hub (GLH).
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events
Research And Development
Labroots Registration (Also interested in)8%
Social Media Promotions1%
Medical Laboratory Technician6%
Clinical Laboratory Scientist5%
Life Science Company6%